Newswise — XimedicaDx, formerly known as Accel Biotech, is proud to unveil their comprehensive rebranding, which is officially being revealed at the 69th AACC Clinical Lab Expo in San Diego. The change comes in alignment with their acquisition by Ximedica, a leading full service medical technologies development firm, in July of 2016. XimedicaDx maintains Accel Biotech’s comprehensive experience and expertise in in-vitro diagnostics and life science product development as Ximedica’s Diagnostics Center of Excellence.
“We’re excited for the chance to showcase our Dx teams’ expertise in microfluidics, optics, automation, and robotics along with the Ximedica brand of human-centric design, technical sophistication, and risk adverse regulatory rigor,” says Tracy MacNeal, President of XimedicaDx. “These combined strengths will bring a cost effective development approach and a high-value customer experience that is reflective of our brand promise.”
With the addition of XimedicaDx, Ximedica enhances their design and development offerings with new core competencies in:
- In Vitro Diagnostics – strengths in developing molecular diagnostic platforms, immunoassay systems, tissue and cell imagers, compact and handheld point-of-care devices and various clinical chemistry analyzers
- Life Science Instrumentation – experience with cellular, nucleic acid, protein, and small molecule analysis in systems ranging from complex multiplex analyzers to agriculture and food testing
- Disposable Development – expertise in microfluidics, reagent storage, material selection, molding and more
Meet with XimedicaDx at booth #845 on August 1-3 at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego, CA.
About Ximedica: Ximedica is a full-service ISO 13485-certified and FDA-registered product development firm. For 30 years Ximedica has provided a unique growth platform enabling organizations to successfully deploy medical technology products into the market. Its headquarters are in Providence, R.I., with offices in Hong Kong, Minneapolis, San Francisco and Los Gatos. In November of 2014, SV Life Sciences, a Boston-based private equity firm, acquired a majority stake in Ximedica, enabling the company to execute its growth strategy. www.ximedica.com
RSS